Applied Genetic Technologies Corp (AGTC):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Applied Genetic Technologies Corp (AGTC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12321
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:59
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Applied Genetic Technologies Corp (AGTC) is a pharmaceutical company that provides development of eye disease cures. The company develops treatments for patients that have diseases caused by broken genes. It offers products such as x-linked retinoschisis, achromatopsia, x-linked retinitis pigmentosa, alpha-1 antitrypsin deficiency and macular degeneration, among others. AGTC’s achromatopsia provides treatment inherited conditions that are associated with visual acuity loss, extreme light sensitivity resulting in daytime blindness, and total loss of color discrimination. The company’s x-linked retinoschisis offers treatment in retinal degeneration affecting young males, presenting with poor vision by school age. It also offers ophthalmology development programs and proof-of-concept data in multiple indications. The company operates through its offices in Alachua and Cambridge, the US, and others. AGTC is headquartered in Alachua, Florida, the US.

Applied Genetic Technologies Corp (AGTC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Applied Genetic Technologies Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Applied Genetic Technologies Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Applied Genetic Technologies Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Applied Genetic Technologies Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Applied Genetic Technologies Corp, Medical Devices Deals, 2012 to YTD 2018 10
Applied Genetic Technologies Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Applied Genetic Technologies Corp, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Applied Genetic Technologies Raises US$37.5 Million In Series B Financing 12
Applied Genetic Technologies Raises US$0.8 Million In Venture Financing 14
Partnerships 15
Applied Genetic Tech Enters into R&D Agreement with Bionic Sight 15
Applied Genetic Technologies Enters into Co-Development Agreement with BCM Families Foundation 16
Applied Genetic Technologies Enters into R&D Agreement with Synpromics 17
Licensing Agreements 18
Biogen Enters into Licensing Agreement with Applied Genetic Technologies 18
Applied Genetic Technologies Enters into Licensing Agreement with 4D Molecular Therapeutics 20
Equity Offering 21
Applied Genetic Tech Plans to Raise up to USD125 Million in Public Offering of Securities 21
Applied Genetic Tech Raises USD30 Million in Private Placement of Shares 23
Applied Genetic Completes Underwriters Exercise of Over-Allotment Option for Public Offering of Shares for USD34.5 Million 25
Applied Genetic Technologies Completes IPO For US$57.5 Million 27
Applied Genetic Technologies Corp – Key Competitors 29
Applied Genetic Technologies Corp – Key Employees 30
Applied Genetic Technologies Corp – Locations And Subsidiaries 31
Head Office 31
Recent Developments 32
Financial Announcements 32
Sep 10, 2018: AGTC announces financial results and business update for the fourth quarter and fiscal year ended June 30, 2018 32
May 08, 2018: AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2018 34
Feb 09, 2018: AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2017 36
Nov 07, 2017: AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2017 38
Sep 13, 2017: AGTC Announces Financial Results and Business Update for the Quarter and Fiscal Year Ended June 30, 2017 40
May 10, 2017: AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2017 42
Feb 08, 2017: AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2016 45
Corporate Communications 47
Sep 24, 2018: AGTC names William Aliski to its board of directors 47
Feb 14, 2018: AGTC Announces Sue Washer, CEO, Elected to Biotechnology Innovation Organization’s Board of Directors 48
Sep 05, 2017: AGTC Appoints Matthew Feinsod, M.D. as Interim Chief Medical Officer 49
Aug 02, 2017: AGTC Appoints William Sullivan as Chief Financial Officer, Andrew Ashe Named General Counsel 50
Product News 51
06/08/2017: AGTC Announces Topline Safety Data for X-Linked Retinoschisis Phase 1/2 Study 51
05/09/2017: AGTC and Collaborators Present New Data on the Natural History of X-Linked Retinoschisis at the Association for Research in Vision and Ophthalmology Annual Meeting 52
04/18/2018: AGTC Doses First Patient in Phase 1/2 Clinical Study of Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa 53
Product Approvals 54
Aug 10, 2017: AGTC Files Investigational New Drug Application for the Treatment of X-linked Retinitis Pigmentosa Caused by Mutations in the RPGR Gene 54
Aug 03, 2017: AGTC Announces U.S. FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa 55
Clinical Trials 56
Aug 07, 2017: Research Published in Molecular Therapy Identifies Optimal Gene-based Therapeutic Construct for X-Linked Retinitis Pigmentosa 56
Other Significant Developments 58
Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day 58
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59

List of Tables
Applied Genetic Technologies Corp, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Applied Genetic Technologies Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Applied Genetic Technologies Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Applied Genetic Technologies Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Applied Genetic Technologies Corp, Deals By Therapy Area, 2012 to YTD 2018 9
Applied Genetic Technologies Corp, Medical Devices Deals, 2012 to YTD 2018 10
Applied Genetic Technologies Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Applied Genetic Technologies Raises US$37.5 Million In Series B Financing 12
Applied Genetic Technologies Raises US$0.8 Million In Venture Financing 14
Applied Genetic Tech Enters into R&D Agreement with Bionic Sight 15
Applied Genetic Technologies Enters into Co-Development Agreement with BCM Families Foundation 16
Applied Genetic Technologies Enters into R&D Agreement with Synpromics 17
Biogen Enters into Licensing Agreement with Applied Genetic Technologies 18
Applied Genetic Technologies Enters into Licensing Agreement with 4D Molecular Therapeutics 20
Applied Genetic Tech Plans to Raise up to USD125 Million in Public Offering of Securities 21
Applied Genetic Tech Raises USD30 Million in Private Placement of Shares 23
Applied Genetic Completes Underwriters Exercise of Over-Allotment Option for Public Offering of Shares for USD34.5 Million 25
Applied Genetic Technologies Completes IPO For US$57.5 Million 27
Applied Genetic Technologies Corp, Key Competitors 29
Applied Genetic Technologies Corp, Key Employees 30

List of Figures
Applied Genetic Technologies Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Applied Genetic Technologies Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Applied Genetic Technologies Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Applied Genetic Technologies Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Applied Genetic Technologies Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Applied Genetic Technologies Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Applied Genetic Technologies Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Applied Genetic Technologies Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Applied Genetic Technologies Corp, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Applied Genetic Technologies Corp (AGTC):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Lennox International Inc.:企業の戦略・SWOT・財務情報
    Lennox International Inc. - Strategy, SWOT and Corporate Finance Report Summary Lennox International Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Equity Residential:企業の戦略・SWOT・財務情報
    Equity Residential - Strategy, SWOT and Corporate Finance Report Summary Equity Residential - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Puncak Niaga Holdings Bhd (PUNCAK):企業の財務・戦略的SWOT分析
    Puncak Niaga Holdings Bhd (PUNCAK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • PharmaZell GmbH:企業の戦略的SWOT分析
    PharmaZell GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • IMPACT Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary IMPACT Therapeutics Inc (IMPACT) is a developer of therapeutics to treat cancer and other life-threatening diseases. The company provides products such as microtubule inhibitors, PARP-1 inhibitors, and Hedgehog pathway inhibitors for oncology. Its PARP-1 inhibitor is an oral bioavailability; …
  • CommInsure:企業の戦略・SWOT・財務情報
    CommInsure - Strategy, SWOT and Corporate Finance Report Summary CommInsure - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Associated Electric Cooperative Inc.:企業の発電所・SWOT分析2018
    Associated Electric Cooperative Inc. - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information …
  • BearingPoint:企業の戦略的SWOT分析
    BearingPoint - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Virgin Islands Water and Power Authority:企業の戦略的SWOT分析
    Virgin Islands Water and Power Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • EarlySense Inc-医療機器分野:企業M&A・提携分析
    Summary EarlySense Inc (EarlySense), a subsidiary of Earlysense Ltd is a medical device company that offers patient care systems. The company offers continuous patient monitoring for heart rate, respiratory rate and motion. It provides central display station, hallway screen, bedside unit, and conta …
  • Tennessee Valley Authority-エネルギー分野:企業M&A・提携分析
    Summary Tennessee Valley Authority (TVA) is a corporate agency providing electricity for business customers, local power companies and distributors. The agency generates power using diverse sources of energy such as hydro, nuclear, coal, diesel generator and other renewable based power plants. TVA p …
  • Qatar Airways Group Q.C.S.C.:企業の戦略・SWOT・財務分析
    Qatar Airways Group Q.C.S.C. - Strategy, SWOT and Corporate Finance Report Summary Qatar Airways Group Q.C.S.C. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Lipigon Pharmaceuticals AB:製薬・医療:M&Aディール及び事業提携情報
    Summary Lipigon Pharmaceuticals AB (Lipigon Pharmaceuticals) is a lipid biology company that discovers and develops novel therapies for lipid disorders and other cardiometabolic risk factors. The company offers developing its products in various therapeutic areas such as cardiovascular and metabolic …
  • Prime Polymer Co Ltd:企業の戦略的SWOT分析
    Prime Polymer Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • The Manufacturers Life Insurance Co:電力:M&Aディール及び事業提携情報
    Summary The Manufacturers Life Insurance Company (Manufacturers Life Insurance) is a financial service provider, based in Canada. The company provides financial protection, and wealth management products and services, and also asset management services to institutional customers. It offers individua …
  • GISA GmbH:企業の戦略的SWOT分析
    GISA GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Jelf Group PLC:企業のM&A・事業提携・投資動向
    Jelf Group PLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Jelf Group PLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Uflex Limited:企業の戦略・SWOT・財務情報
    Uflex Limited - Strategy, SWOT and Corporate Finance Report Summary Uflex Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Bulgarian Telecommunications Company (VIVACOM):企業の戦略的SWOT分析
    Bulgarian Telecommunications Company (VIVACOM) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitor …
  • Grupo Grana y Montero SAA (GRAMONC1):石油・ガス:M&Aディール及び事業提携情報
    Summary Grupo Grana y Montero SAA (Grana y Montero) is a group company that provides engineering and infrastructure services. The company’s business areas include engineering and construction, infrastructure development, real estate and technical services. It provides engineering procurement and con …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆